

1 **SARS-CoV-2 Omicron subvariants Spike recognition and neutralization elicited after the**  
2 **third dose of mRNA vaccine**

3 Alexandra Tauzin<sup>1,2</sup>, Alexandre Nicolas<sup>1,2,10</sup>, Shilei Ding<sup>1,10</sup>, Mehdi Benlarbi<sup>1,2</sup>, Halima Medjahed<sup>1</sup>,  
4 Debashree Chatterjee<sup>1</sup>, Katrina Dionne<sup>1,2</sup>, Shang Yu Gong<sup>1,3</sup>, Gabrielle Gendron-Lepage<sup>1</sup>, Yuxia  
5 Bo<sup>4</sup>, Josée Perreault<sup>5</sup>, Guillaume Goyette<sup>1</sup>, Laurie Gokool<sup>1</sup>, Pascale Arlotto<sup>1</sup>, Chantal  
6 Morrisseau<sup>1</sup>, Cécile Tremblay<sup>1,2</sup>, Valérie Martel-Laferrrière<sup>1,2</sup>, Gaston De Serres<sup>6</sup>, Inès Levade<sup>7</sup>,  
7 Daniel E. Kaufmann<sup>1,8,9</sup>, Marceline Côté<sup>4</sup>, Renée Bazin<sup>5</sup> and Andrés Finzi<sup>1,2,3,11,\*</sup>

8  
9 <sup>1</sup>Centre de Recherche du CHUM, Montreal, QC, H2X 0A9 Canada

10 <sup>2</sup>Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, H2X  
11 0A9, Canada

12 <sup>3</sup>Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada

13 <sup>4</sup>Department of Biochemistry, Microbiology and Immunology, and Centre for Infection, Immunity, and  
14 Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada

15 <sup>5</sup>Héma-Québec, Affaires Médicales et Innovation, Quebec, QC G1V 5C3, Canada

16 <sup>6</sup>Institut National de Santé Publique du Québec, Quebec, QC, H2P 1E2, Canada

17 <sup>7</sup>Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-  
18 de-Bellevue, QC H9X 3R5, Canada.

19 <sup>8</sup>Département de Médecine, Université de Montréal, Montreal, QC, H3T 1J4, Canada

20 <sup>9</sup>Division of Infectious Diseases, Department of Medicine, University Hospital of Lausanne and University  
21 of Lausanne, Lausanne, CH-1011, Switzerland

22  
23 <sup>10</sup>These authors contributed equally

24 <sup>11</sup>Lead contact

25 \*Correspondence: [andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca) (A.F.)

26  
27

28 **SUMMARY**

29           Several SARS-CoV-2 Omicron subvariants have recently emerged, becoming the  
30 dominant circulating strains in many countries. These variants contain a large number of  
31 mutations in their Spike glycoprotein, raising concerns about vaccine efficacy. In this study, we  
32 evaluate the ability of plasma from a cohort of individuals that received three doses of mRNA  
33 vaccine to recognize and neutralize these Omicron subvariant Spikes. We observed that BA.4/5  
34 and BQ.1.1 Spikes are markedly less recognized and neutralized compared to the D614G and  
35 the other Omicron subvariant Spikes tested. Also, individuals who have been infected before or  
36 after vaccination present better humoral responses than SARS-CoV-2 naïve vaccinated  
37 individuals, thus indicating that hybrid immunity generates better humoral responses against  
38 these subvariants.

39

40 **Keywords:** Coronavirus, COVID-19, SARS-CoV-2, Third mRNA vaccine dose, Spike  
41 glycoproteins, B cell responses, Humoral responses, Neutralization, Omicron subvariants, hybrid  
42 immunity

## 43 INTRODUCTION

44 The SARS-CoV-2 Omicron variant BA.1 emerged at the end of 2021 and rapidly became  
45 the dominant circulating strain in the world <sup>1,2</sup>. Since its emergence, several sublineages of  
46 Omicron rapidly replaced the BA.1 variant due to higher transmission rates. BA.2 became the  
47 dominant circulating strain in spring 2022 <sup>3,4</sup>, and currently the BA.4 and BA.5 variants [sharing  
48 the same mutations in their Spike (S) glycoproteins, named BA.4/5 S in the manuscript], are the  
49 dominant circulating strains in several countries <sup>5-8</sup>. BA.2.75, BA.4.6 and BQ.1.1 have emerged  
50 more recently and are spreading worldwide <sup>9,10</sup>.

51 It was previously shown that poor humoral responses against BA.1 and BA.2 variants were  
52 observed after two doses of mRNA vaccine <sup>11-13</sup>. We and other reported that an extended interval  
53 between the first two doses of mRNA vaccine led to strong humoral responses to several variants  
54 of concern (VOCs) including BA.1 and BA.2 after the second dose of mRNA vaccine <sup>14-16</sup>.  
55 However, a third dose of mRNA vaccine led to an increase of humoral responses against these  
56 Omicron variants, regardless of the interval between doses <sup>11,13,16,17</sup>. Previous studies also  
57 reported that breakthrough infection (BTI) in vaccinated people induced strong neutralizing Abs  
58 against VOCs, including BA.1 <sup>18,19</sup>. However, recent studies have shown that BA.4/5, BA.2.75,  
59 BA.4.6 and BQ.1.1 appear to be more resistant than BA.1 and BA.2 to vaccination and  
60 monoclonal antibodies (Abs) <sup>20-26</sup>.

61 In this study, we analyzed the ability of plasma from vaccinated individuals to recognize  
62 and neutralize pseudoviral particles bearing different Omicron subvariant Spikes four weeks  
63 (median [range]: 30 days [20-44 days]) and four months (median [range]: 121 days [92-135 days])  
64 after the third dose of mRNA vaccine. This study was conducted in a cohort of individuals who  
65 received their first two doses with a 16-weeks extended interval (median [range]: 110 days [54-  
66 146 days]) and their third dose seven months after the second dose (median [range]: 211 days  
67 [151-235 days]). The cohort included 15 naïve individuals who were never infected with SARS-

68 CoV-2, 15 previously infected (PI) individuals who were infected during the first wave of COVID-  
69 19 in early 2020 (before the advent of the alpha variant and other VOCs) and before vaccination,  
70 and 15 BTI individuals who were infected after vaccination. All BTI individuals were infected  
71 between mid-December 2021 and May 2022, when almost only Omicron variants (BA.1 and BA.2)  
72 were circulating in Quebec. Basic demographic characteristics of the cohorts and detailed  
73 vaccination time points are summarized in Table 1 and Figure 1A.

74

## 75 **RESULTS**

### 76 **RBD-specific IgG and associated avidity.**

77 We first measured the level of anti-RBD IgG four weeks and four months after the third  
78 dose of mRNA vaccine in naïve, BTI and PI individuals (Figure 1A) by a well described ELISA  
79 assay<sup>16,27-30</sup> (Figure 1B). Four weeks after the third dose, we did not observe significant  
80 differences in the level of IgG between the three groups. Four months after the third dose, we  
81 observed that the level of IgG significantly decreased in all groups, but to a higher extent in naïve  
82 individuals. No significant differences were observed between naïve, BTI and PI individuals four  
83 months after the boost. We also measured the avidity of anti-RBD IgG induced after the third dose  
84 of mRNA vaccine using a previously described assay<sup>28,31</sup>. Four weeks after the third dose, we  
85 observed that naïve donors had IgG with lower avidity, although we only measured significant  
86 difference with BTI individuals (Figure 1C). Four months after the third dose, the avidity of these  
87 IgG slightly decreased for naïve individuals but remained stable for BTI and PI groups.

88

### 89 **RBD-specific B cell responses after the third dose of mRNA vaccine.**

90 We also monitored the SARS-CoV-2-specific B cells (identified as CD19+ CD20+) by flow  
91 cytometry, using two recombinant RBD protein probes labeled with two different fluorochromes

92 (Alexa Fluor 594 and Alexa Fluor 488) (Figure S1A)<sup>30,32</sup>. Four weeks after the third dose of mRNA  
93 vaccine, no significant differences in the level of circulating B cells were observed between the  
94 three groups (Figure 1D). Four months after the boost, this level significantly decreased for naïve  
95 donors but not for individuals with hybrid immunity (PI and BTI). For BTI individuals, we observed  
96 an increase, with some donors presenting a higher level of circulating RBD-specific B cells,  
97 probably due to recent infection.

98

### 99 **Recognition of SARS-CoV-2 Spike variants by plasma from vaccinated individuals.**

100 We next measured the ability of plasma to recognize the SARS-CoV-2 D614G and different  
101 Omicron subvariants S in vaccinated naïve, PI and BTI individuals four weeks and four months  
102 after the third dose of mRNA vaccine. Spike expression levels of the Spike variants were  
103 normalized to the signal obtained with the conformationally independent anti-S2 neutralizing CV3-  
104 25 antibody<sup>33-35</sup> that efficiently recognized all these Spikes despite their various mutations (Figure  
105 S1B, S2A-C). Four weeks after the third dose of mRNA vaccine, we observed that plasma from  
106 PI individuals recognized more efficiently the D614G S than naïve individuals (Figure 2A). We  
107 also observed that BTI individuals recognized the D614G S as efficiently as the PI individuals.  
108 Four months after the third dose, the level of recognition of the D614G S decreased for the three  
109 groups but with a more significant reduction in the naïve group. For the BA.2, BA.4/5 and BQ.1.1  
110 S, naïve and BTI had the same level of recognition four weeks after the third dose, and this level  
111 was significantly lower than for PI individuals (Figure 2B-C, F). For BA.2.75 and BA.4.6 S, we only  
112 observed significant differences between naïve and PI individuals four weeks after the third dose  
113 (Figure 2D-E). Four months after the third dose, we observed a significant decrease of the  
114 recognition for naïve and PI individuals, with the exception of the BQ.1.1 S for which the level  
115 remained stable in the PI group (Figure 2A-F). For the BTI group, the level of recognition remained  
116 more stable and reached the same level than for the PI group for all tested Spikes. We also

117 observed that the BA.4/5 and the BQ.1.1 S were always less recognized than the D614G and  
118 other Omicron subvariants S at both time points for all groups (Figure 2G-H).

119

## 120 **Neutralizing activity of the vaccine-elicited antibodies.**

121 We also evaluated the neutralizing activity against pseudoviral particles bearing these  
122 Spikes in the three groups. Of note, all Spikes were incorporated into pseudoviral particles to  
123 similar extents (Figure S2C) and had similar levels of infectivity in our assay (Figure S2D). In  
124 agreement with the pattern of S recognition, PI individuals neutralized more efficiently all the S  
125 variants tested than naïve individuals four weeks after the third dose (Figure 3A-F). For the BTI  
126 group, the level of neutralizing Abs was intermediate between the two other groups. Four months  
127 after the third dose, we did not observe significant differences between PI and BTI individuals. In  
128 contrast, the naïve group neutralized less efficiently the D614G, and Omicron subvariants S  
129 (Figure 3A-F). Four weeks after the third dose, no significant difference in the level of  
130 neutralization was measured between the D614G and BA.2 S for the three groups (Figure 2G).  
131 In contrast, the other Omicron variants S were more resistant to neutralization than the D614G S  
132 in all groups. Four months after the third dose, weak or no neutralizing activity against Omicron  
133 subvariants S was detected in most naïve individuals (Figure 3B-F, H). For BTI and PI individuals,  
134 although neutralizing activity was higher than in naïve individuals, the BA.4/5, BA.2.75, BA.4.6  
135 and BQ.1.1 S were also significantly less neutralized than the D614G and, in some instances,  
136 BA.2 S (Figure 3B-F, H).

137

138 **DISCUSSION**

139 More than two years after its emergence, and although an important proportion of the  
140 world population has received several doses of vaccine, the SARS-CoV-2 variants continue to  
141 circulate globally. In recent months, new sub-variants of Omicron emerged, carrying increasing  
142 numbers of mutations making them more transmissible and resistant to vaccination and  
143 monoclonal antibodies treatment <sup>8,17,20–22,25</sup>. In agreement with this, we observed that the BA.4/5,  
144 BA.2.75, BA.4.6 and BQ.1.1 S were less efficiently recognized and neutralized than the D614G  
145 and the BA.2 S by plasma from individuals who received three doses of mRNA vaccine.

146 Several studies reported that poor neutralizing activity against VOCs was observed after  
147 two doses of mRNA vaccine, but a third dose strongly improved this response <sup>11,16,36</sup>. However,  
148 when the second dose of vaccine was administered with an extended 16-weeks interval, higher  
149 humoral responses against VOCs (including BA.1 and BA.2) were observed after the second  
150 dose of vaccine <sup>14</sup>, that were not increased by a booster dose <sup>16</sup>. Therefore, there is no evidence  
151 that additional doses of the original SARS-CoV-2 vaccines after the third dose will result in  
152 increased responses against VOCs.

153 The Omicron variants spread more easily in vaccinated individuals than pre-Omicron  
154 variants <sup>37,38</sup>. Interestingly, it was recently shown that previous infection with an Omicron variant  
155 prevents reinfection more efficiently than previous infection with a pre-Omicron variant <sup>39,40</sup>, thus  
156 suggesting that new vaccines based on Omicron variants may generate humoral responses more  
157 likely to control Omicron sub-variants.

158 It was previously shown that hybrid immunity due to SARS-CoV-2 infection followed by  
159 vaccination confers stronger immune responses than vaccination alone <sup>16,32,40,41</sup>. Accordingly,  
160 here we observed that individuals with BTI had the same level of S recognition and neutralization  
161 than individuals previously infected supporting the concept that hybrid protection is similar

162 whatever the order of infection and vaccination. However, the durability of these responses  
163 remains unknown.

164 In conclusion, virus recognition and neutralizing activity induced by current mRNA vaccine  
165 are low against Omicron subvariants, rapidly decline over 4 months in naïve individuals, and will  
166 likely decrease further with future SARS-CoV-2 evolution. There is a need to rapidly develop new  
167 generations of vaccines that will elicit broader and less labile protection.

168

## 169 **LIMITATIONS OF THE STUDY**

170 One of the limitations of the study is that for most BTI individuals, we do not have the exact  
171 day of infection and by which variant. We can only confirm whether they were infected before the  
172 first timepoint studied or between the 2 timepoints. Furthermore, it is very likely that some PI  
173 individuals were exposed a second time. However, in our study, no case of infection was  
174 confirmed by PCR in PI group, and since they were already infected a first time, we cannot  
175 conclude that a positive anti-N corresponds to a new infection or to the first. Finally, while we did  
176 not observe major differences in infectivity with our pseudoviral particles, it is possible that  
177 differences in infectivity and replication exist when using authentic live viruses. For this reason  
178 we only report on plasma neutralization profiles, which were shown to be similar between  
179 pseudoviral particles and authentic viruses and have been largely used by the field to inform on  
180 neutralizing responses elicited by natural infection and vaccination <sup>42–46</sup>.

## 181 **ACKNOWLEDGMENTS**

182 The authors are grateful to the individuals who participated in this study. The authors thank  
183 the CRCHUM BSL3 and Flow Cytometry Platforms for technical assistance. This work was  
184 supported by le Ministère de l'Économie et de l'Innovation du Québec, Programme de soutien  
185 aux organismes de recherche et d'innovation to A.F. and by the Fondation du CHUM. This work



186 was also supported by a CIHR foundation grant #352417, by a CIHR operating Pandemic and  
187 Health Emergencies Research grant #177958, by an Exceptional Fund COVID-19 from the  
188 Canada Foundation for Innovation (CFI) #41027 to A.F. and by a FRQS Merit Research Scholar  
189 award (# 268471) to D.E.K. Work on variants presented was also supported by the Sentinelle  
190 COVID Quebec network led by the LSPQ in collaboration with Fonds de Recherche du Québec  
191 Santé (FRQS) to A.F. This work was also partially supported by a CIHR COVID-19 rapid response  
192 grant (OV3 170632) and CIHR stream 1 SARS-CoV-2 Variant Research to M.C. A.F. is the  
193 recipient of Canada Research Chair on Retroviral Entry no. RCHS0235 950-232424. M.C is a  
194 Tier II Canada Research Chair in Molecular Virology and Antiviral Therapeutics (950-232840).  
195 C.T. is the Pfizer/Université de Montréal Chair on HIV translational research. A.T. was supported  
196 by MITACS Accélération postdoctoral fellowship. M.B. was the recipient of a CIHR master's  
197 scholarship award. The funders had no role in study design, data collection and analysis, decision  
198 to publish, or preparation of the manuscript. We declare no competing interests.

199

## 200 **AUTHOR CONTRIBUTIONS**

201 A.T. and A.F. conceived the study. A.T., A.N., S.D., D.C., M.B., K.D., S.Y.G., G.G.L., H.M.,  
202 G.G., J.P., Y.B., and A.F. performed, analyzed, and interpreted the experiments. A.T. performed  
203 statistical analysis. G.G.L., H.M., G.G., M.C., and A.F. contributed unique reagents. L.G., P.A.,  
204 C.M., C.T., and V.M.-L. collected and provided clinical samples. R.B., G.D.S., D.E.K. and I.L.  
205 provided scientific input related to VOCs and vaccine efficacy. A.T. and A.F. wrote the manuscript  
206 with inputs from others. Every author has read, edited, and approved the final manuscript.

207

## 208 **DECLARATION OF INTERESTS**

209 The authors declare no conflict of interest.

210 **FIGURE LEGENDS**

211 **Figure 1. Anti-RBD IgG level, associated anti-RBD avidity and RBD-Specific B cell**  
212 **responses in plasma from naïve, BTI and PI individuals after the third dose of mRNA**  
213 **vaccine.**

214 **(A)** SARS-CoV-2 vaccine cohort design. The yellow box represents the period under study. **(B-**  
215 **C)** Indirect ELISAs were performed by incubating plasma samples from naïve, BTI or PI  
216 individuals collected 4 weeks or 4 months after the third dose of mRNA vaccine with recombinant  
217 SARS-CoV-2 RBD protein. Anti-RBD Ab binding was detected using HRP-conjugated anti-human  
218 IgG. **(B)** RLU values obtained were normalized to the signal obtained with the anti-RBD CR3022  
219 mAb present in each plate. **(C)** The RBD avidity index corresponded to the value obtained with  
220 the stringent (8M urea) ELISA divided by that obtained without urea. **(D)** The frequencies of RBD+  
221 B cells were measured by flow cytometry. **(B-D)** Plasma samples were grouped in two different  
222 time points (4 weeks and 4 months). Naïve, BTI and PI individuals are represented by red, yellow  
223 and black points respectively, undetectable measures are represented as white symbols, and  
224 limits of detection are plotted. Error bars indicate means  $\pm$  SEM. (\*  $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P <$   
225  $0.001$ ; \*\*\*\*  $P < 0.0001$ ; ns, non-significant). For all groups,  $n=15$  **(B-C)** or  $n=10$  **(D)**.

226

227 **Figure 2. Recognition of SARS-CoV-2 Spike variants by plasma from naïve, BTI and PI**  
228 **individuals after the third dose of mRNA vaccine.**

229 **(A-G)** 293T cells were transfected with the indicated full-length S from different SARS-CoV-2  
230 variants and stained with the CV3-25 mAb or with plasma from naïve, BTI or PI individuals  
231 collected 4 weeks or 4 months after the third dose of mRNA vaccine and analyzed by flow  
232 cytometry. The values represent the MFI normalized by CV3-25 Ab binding. **(A-F)** Plasma  
233 samples were grouped in two different time points (4 weeks and 4 months). **(G-H)** Binding of

234 plasma collected at 4 weeks (**G**) and 4 months (**H**) post vaccination were measured. Naïve, BTI  
235 and PI individuals are represented by red, yellow and black points respectively, undetectable  
236 measures are represented as white symbols, and limits of detection are plotted. Error bars  
237 indicate means  $\pm$  SEM. (\* P < 0.05; \*\* P < 0.01; \*\*\* P < 0.001; \*\*\*\* P < 0.0001; ns, non-significant).  
238 For all groups, n=15.

239

240 **Figure 3. Neutralization activity of SARS-CoV-2 Spike variants by plasma from naïve, BTI**  
241 **and PI individuals after the third dose of mRNA vaccine.**

242 (**A-G**) Neutralization activity was measured by incubating pseudoviruses bearing SARS-CoV-2 S  
243 glycoproteins, with serial dilutions of plasma for 1 h at 37°C before infecting 293T-ACE2 cells.  
244 Neutralization half maximal inhibitory serum dilution (ID<sub>50</sub>) values were determined using a  
245 normalized non-linear regression using GraphPad Prism software. (**A-F**) Plasma samples were  
246 grouped in two different time points (4 weeks and 4 months). (**G-H**) Neutralization activity of  
247 plasma collected at 4 weeks (**G**) and 4 months (**H**) post vaccination were measured. Naïve, BTI  
248 and PI individuals are represented by red, yellow and black points respectively, undetectable  
249 measures are represented as white symbols, and limits of detection are plotted. Error bars  
250 indicate means  $\pm$  SEM. (\* P < 0.05; \*\* P < 0.01; \*\*\* P < 0.001; \*\*\*\* P < 0.0001; ns, non-significant).  
251 For all groups, n=15.

252

253

254

255 **Table 1. Characteristics of the vaccinated SARS-CoV-2 cohorts**

		Entire cohort	Naïve	Breakthrough infection <sup>b</sup>	Previously infected
<b>Number</b>		45	15	15	15
<b>Age</b>		51 (24-67)	54 (24-67)	43 (30-64)	48 (29-65)
<b>Gender</b>	<b>Male (n)</b>	17	4	5	8
	<b>Female (n)</b>	28	11	10	7
<b>Vaccine</b>	<b>1<sup>st</sup> dose</b>	Pfz=43 ; M=1 ; AZ=1	Pfz=14 ; M=1	Pfz=14 ; AZ=1	Pfz=15
	<b>2<sup>nd</sup> dose</b>	Pfz=43 ; M=1 ; AZ=1	Pfz=14 ; M=1	Pfz=14 ; AZ=1	Pfz=15
	<b>3<sup>rd</sup> dose</b>	Pfz=40 ; M=5	Pfz=15	Pfz=14 ; AZ=1	Pfz=11 ; AZ=4
<b>Days between symptom onset and the 1<sup>st</sup> dose<sup>a</sup></b>		N/A	N/A	N/A	288 (166-321)
<b>Days between the 1<sup>st</sup> and 2<sup>nd</sup> dose<sup>a</sup></b>		110 (54-146)	109 (65-120)	110 (54-113)	112 (90-146)
<b>Days between the 2<sup>nd</sup> and 3<sup>rd</sup> dose<sup>a</sup></b>		211 (151-235)	210 (184-227)	215 (151-224)	219 (187-235)
<b>Days between the 3<sup>rd</sup> dose and 4W</b>		30 (20-44)	32 (21-37)	28 (20-38)	33 (24-44)
<b>Days between the 3<sup>rd</sup> dose and 4M</b>		121 (92-135)	124 (105-135)	121 (92-131)	119 (111-127)

256 <sup>a</sup> Values displayed are medians, with ranges in parentheses. Continuous variables were compared by using Kruskal-  
 257 Wallis tests.  $p < 0.05$  was considered statistically significant for all analyses. No statistical differences were found for  
 258 any of the parameter tested between the different groups. Pfz= Pfizer/BioNtech BNT162b2, M= Moderna mRNA-1273,  
 259 AZ= AstraZeneca ChAdOx1. <sup>b</sup> All Breakthrough infection individuals were infected between mid-December 2021 and  
 260 May 2022, when almost only Omicron variants (BA.1 and BA.2) were circulating in Quebec. 6 BTI individuals were  
 261 infected before the time point collected 4 weeks after the third dose and 9 BTI individuals were infected between the  
 262 two time points.  
 263

264

265 **STAR METHODS**

266

267 **RESOURCE AVAILABILITY**

268

269 **Lead contact**

270 Further information and requests for resources and reagents should be directed to and will be

271 fulfilled by the lead contact, Andrés Finzi ([andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca)).

272

273 **Materials availability**

274 All unique reagents generated during this study are available from the Lead contact without  
275 restriction.

276

277 **Data and code availability**

278 • All data reported in this paper will be shared by the lead contact  
279 ([andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca)) upon request.

280 • This paper does not report original code.

281 • Any additional information required to reanalyze the data reported in this paper is available  
282 from the lead contact ([andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca)) upon request.

283

284 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

285

286 **Ethics Statement**

287 All work was conducted in accordance with the Declaration of Helsinki in terms of informed  
288 consent and approval by an appropriate institutional board. Blood samples were obtained from  
289 donors who consented to participate in this research project at CHUM (19.381). Plasmas and

290 PBMCs were isolated by centrifugation and Ficoll gradient, and samples stored at -80°C and in  
291 liquid nitrogen respectively, until use.

292

### 293 **Human subjects**

294 The study was conducted in 15 SARS-CoV-2 naïve individuals (4 males and 11 females; age  
295 range: 24-67 years), 15 SARS-CoV-2 breakthrough infection individuals (5 males and 10 females;  
296 age range: 30-64 years) infected after the second or third dose of mRNA vaccine (6 BTI were  
297 infected before the time point collected 4 weeks after the third dose and 9 individuals were infected  
298 between the two time points), and 15 SARS-CoV-2 previously infected individuals (8 males and  
299 7 females; age range: 29-65 years) infected before vaccination during the first wave of COVID-  
300 19 in march-may 2020. This information is presented in table 1. No specific criteria such as  
301 number of patients (sample size), gender, clinical or demographic were used for inclusion, beyond  
302 PCR confirmed SARS-CoV-2 infection in adults before vaccination for PI group, PCR confirmed  
303 SARS-CoV-2 infection or anti-N positive in adults after vaccination for BTI group and no detection  
304 of Abs recognizing the N protein for naïve individuals.

305

### 306 **Plasma and antibodies**

307 Plasmas were isolated by centrifugation with Ficoll gradient, heat-inactivated for 1 hour at 56°C  
308 and stored at -80°C until use in subsequent experiments. Healthy donor's plasmas, collected  
309 before the pandemic, were used as negative controls, and used to calculate the seropositivity  
310 threshold in our ELISAs and flow cytometry assays (data not shown). The RBD-specific  
311 monoclonal antibody CR3022 was used as a positive control in ELISA assays, and the  
312 conformationally independent S2-specific monoclonal antibody CV3-25 was used as a positive  
313 control and to normalize Spike expression in our flow cytometry assays, as described <sup>34,47-49</sup>.  
314 Horseradish peroxidase (HRP)-conjugated Abs able to detect the Fc region of human IgG

315 (Invitrogen) was used as secondary Abs to detect Ab binding in ELISA experiments. Alexa Fluor-  
316 647-conjugated goat anti-human Abs able to detect all Ig isotypes (anti-human IgM+IgG+IgA;  
317 Jackson ImmunoResearch Laboratories) were used as secondary Abs to detect plasma binding  
318 in flow cytometry experiments.

319

## 320 **Cell lines**

321 293T human embryonic kidney cells (obtained from ATCC) and Cf2.Th cells (a kind gift from  
322 Joseph Sodroski, Dana Farber Cancer Institute (DFCI), Boston, MA, USA) were maintained at  
323 37°C under 5% CO<sub>2</sub> in Dulbecco's modified Eagle's medium (DMEM) (Wisent) containing 5% fetal  
324 bovine serum (FBS) (VWR) and 100 µg/ml of penicillin-streptomycin (Wisent). 293T-ACE2 cell  
325 line was previously reported <sup>29</sup>.

326

## 327 **METHOD DETAILS**

### 328 **Plasmids**

329 The plasmids encoding the SARS-CoV-2 Spike variants were previously described <sup>16,48,50</sup>. The  
330 plasmids encoding the BA.4/5, BA.2.75, BA.4.6 and BQ.1.1 Spike was generated by overlapping  
331 PCR using the BA.2 SARS-CoV-2 Spike gene as a template and cloned in pCAGGS. All  
332 constructs were verified by Sanger sequencing. Spike variant sequences are outlined in Figure  
333 S2A. The pNL4.3 R-E- Luc was obtained from the NIH AIDS Reagent Program. The vesicular  
334 stomatitis virus G (VSV-G)-encoding plasmid (pSVCMV-IN-VSV-G) was previously described <sup>29</sup>.

335

### 336 **Protein expression and purification**

337 FreeStyle 293F cells (Invitrogen) were grown in FreeStyle 293F medium (Invitrogen) to a density  
338 of 1×10<sup>6</sup> cells/mL at 37°C with 8% CO<sub>2</sub> with regular agitation (150 rpm). Cells were transfected  
339 with a plasmid coding for SARS-CoV-2 S WT RBD <sup>50</sup> using ExpiFectamine 293 transfection  
340 reagent, as directed by the manufacturer (Invitrogen). One week later, cells were pelleted and

341 discarded. Supernatants were filtered using a 0.22  $\mu\text{m}$  filter (Thermo Fisher Scientific). The  
342 recombinant RBD proteins were purified by nickel affinity columns, as directed by the  
343 manufacturer (Invitrogen). The RBD preparations were dialyzed against phosphate-buffered  
344 saline (PBS) and stored in aliquots at  $-80^{\circ}\text{C}$  until further use. To assess purity, recombinant  
345 proteins were loaded on SDS-PAGE gels and stained with Coomassie Blue.

346

### 347 **Enzyme-linked immunosorbent assay (ELISA) and RBD avidity index**

348 The SARS-CoV-2 WT RBD ELISA assay used was previously described<sup>29,50</sup>. Briefly, recombinant  
349 SARS-CoV-2 WT RBD proteins (2.5 mg/mL), or bovine serum albumin (BSA) (2.5 mg/mL) as a  
350 negative control, were prepared in PBS and were adsorbed to plates (MaxiSorp Nunc) overnight  
351 at  $4^{\circ}\text{C}$ . Coated wells were subsequently blocked with blocking buffer (Tris-buffered saline [TBS]  
352 containing 0.1% Tween20 and 2% BSA) for 1h at room temperature. Wells were then washed  
353 four times with washing buffer (Tris-buffered saline [TBS] containing 0.1% Tween20). CR3022  
354 mAb (50 ng/mL) or a 1/500 dilution of plasma were prepared in a diluted solution of blocking buffer  
355 (0.1% BSA) and incubated with the RBD-coated wells for 90 min at room temperature. Plates  
356 were washed four times with washing buffer followed by incubation with secondary Abs (diluted  
357 in a diluted solution of blocking buffer (0.4% BSA)) for 1h at room temperature, followed by four  
358 washes. To calculate the RBD-avidity index, we performed in parallel a stringent ELISA, where  
359 the plates were washed with a chaotropic agent, 8M of urea, added of the washing buffer. This  
360 assay was previously described<sup>31</sup>. HRP enzyme activity was determined after the addition of a  
361 1:1 mix of Western Lightning oxidizing and luminol reagents (Perkin Elmer Life Sciences). Light  
362 emission was measured with a LB942 TriStar luminometer (Berthold Technologies). Signal  
363 obtained with BSA was subtracted for each plasma and was then normalized to the signal  
364 obtained with CR3022 present in each plate. The seropositivity threshold was established using  
365 the following formula: mean of pre-pandemic SARS-CoV-2 negative plasma + (3 standard  
366 deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma).



367

### 368 **SARS-CoV-2-specific B cells characterization**

369 To detect SARS-CoV-2-specific B cells, we conjugated recombinant RBD proteins with Alexa  
370 Fluor 488 or Alexa Fluor 594 (Thermo Fisher Scientific) according to the manufacturer's protocol.  
371  $2 \times 10^6$  frozen PBMCs from SARS-CoV-2 naïve, BTI and PI donors were prepared at a final  
372 concentration of  $4 \times 10^6$  cells/mL in RPMI 1640 medium (GIBCO) supplemented with 10% of fetal  
373 bovine serum (Seradigm), Penicillin/Streptomycin (GIBCO) and HEPES (GIBCO). After a rest of  
374 2h at 37°C and 5% CO<sub>2</sub>, cells were stained using Aquavid viability marker (GIBCO) in DPBS  
375 (GIBCO) at 4°C for 20 min. The detection of SARS-CoV-2-antigen specific B cells was done by  
376 adding the RBD probes to the antibody cocktail listed in Table S1. Staining was performed at 4°C  
377 for 30 min and cells were fixed using 2% paraformaldehyde at 4°C for 15 min. Stained PBMC  
378 samples were acquired on Symphony cytometer (BD Biosciences) and analyzed using FlowJo  
379 v10.8.0 software and the gating strategy presented in Figure S1A.

380

381

### 382 **Cell surface staining and flow cytometry analysis**

383 293T were transfected with full-length SARS-CoV-2 Spikes and a green fluorescent protein (GFP)  
384 expressor (pIRES2-eGFP; Clontech) using the calcium-phosphate method. Two days post-  
385 transfection, Spike-expressing 293T cells were stained with the CV3-25 Ab (5 µg/mL) as control  
386 or plasma from naïve, BTI or PI individuals (1:250 dilution) for 45 min at 37°C. AlexaFluor-647-  
387 conjugated goat anti-human IgG (1/1000 dilution) were used as secondary Abs. The percentage  
388 of Spike-expressing cells (GFP + cells) was determined by gating the living cell population based  
389 on viability dye staining (Aqua Vivid, Invitrogen). Samples were acquired on a LSR II cytometer  
390 (BD Biosciences), and data analysis was performed using FlowJo v10.7.1 (Tree Star) using the  
391 gating strategy presented in Figure S1B. The conformationally-independent anti-S2 antibody  
392 CV3-25 was used to normalize Spike expression, as reported<sup>33–35,48</sup>. CV3-25 was shown to be

393 effective against all Spike variants (Figure S2B-C). The Median Fluorescence intensities (MFI)  
394 obtained with plasma were normalized to the MFI obtained with CV3-25 and presented as  
395 percentage of CV3-25 binding.

396

### 397 **Pseudoviral infectivity**

398 293T cells were transfected with the lentiviral vector pNL4.3 R-E- Luc (NIH AIDS Reagent  
399 Program) and plasmid encoding for the indicated S glycoprotein (D614G, BA.2, BA.4/5, BA.2.75,  
400 BA.4.6 or BQ.1.1) at a ratio of 10:1. Two days post-transfection, cell supernatants were harvested  
401 and stored at -80°C until use. The RT activity was evaluated by measure of the incorporation of  
402 [*methyl*-3H]TTP into cDNA of a poly(rA) template in the presence of virion-associated RT and  
403 oligo(dT). Normalized amount of RT activity pseudoviral particles were added to 293T-ACE2  
404 target cells for 48 h at 37°C. Then, cells were lysed by the addition of 30 µL of passive lysis buffer  
405 (Promega) followed by one freeze-thaw cycle. An LB942 TriStar luminometer (Berthold  
406 Technologies) was used to measure the luciferase activity of each well after the addition of 100  
407 µL of luciferin buffer (15mM MgSO<sub>4</sub>, 15mM KPO<sub>4</sub> [pH 7.8], 1mM ATP, and 1mM dithiothreitol)  
408 and 50 µL of 1mM d-luciferin potassium salt (Thermo Fisher Scientific). RLU values obtained were  
409 normalized to D614G.

410

### 411 **Virus neutralization assay**

412 To produce SARS-CoV-2 pseudoviruses, 293T cells were transfected with the lentiviral vector  
413 pNL4.3 R-E- Luc (NIH AIDS Reagent Program) and a plasmid encoding for the indicated S  
414 glycoprotein (D614G, BA.2, BA.4/5, BA.2.75, BA.4.6 or BQ.1.1) at a ratio of 10:1. Two days post-  
415 transfection, cell supernatants were harvested and stored at -80°C until use. For the  
416 neutralization assay, 293T-ACE2 target cells were seeded at a density of 1×10<sup>4</sup> cells/well in 96-  
417 well luminometer-compatible tissue culture plates (PerkinElmer) 24h before infection. Pseudoviral  
418 particles were incubated with several plasma dilutions (1/50; 1/250; 1/1250; 1/6250; 1/31250) for

419 1h at 37°C and were then added to the target cells followed by incubation for 48h at 37°C. Cells  
420 were lysed by the addition of 30 µL of passive lysis buffer (Promega) followed by one freeze-thaw  
421 cycle. An LB942 TriStar luminometer (Berthold Technologies) was used to measure the luciferase  
422 activity of each well after the addition of 100 µL of luciferin buffer (15mM MgSO<sub>4</sub>, 15mM  
423 KH<sub>2</sub>PO<sub>4</sub> [pH 7.8], 1mM ATP, and 1mM dithiothreitol) and 50 µL of 1mM d-luciferin potassium salt  
424 (Prolume). The neutralization half-maximal inhibitory dilution (ID<sub>50</sub>) represents the plasma dilution  
425 to inhibit 50% of the infection of 293T-ACE2 cells by pseudoviruses.

426

### 427 **Virus Capture Assay**

428 The assay was previously described <sup>51</sup>. Briefly, pseudoviral particles were produced by  
429 transfecting 2×10<sup>6</sup> 293T cells with pNL4.3 R-E- Luc (3.5 µg), pSVCMV-IN-VSV-G (1 µg) and  
430 plasmids encoding for SARS-CoV-2 Spike glycoproteins (3.5 µg) using the standard calcium  
431 phosphate protocol. 48 hours later, virion-containing supernatants were collected. White  
432 MaxiSorp ELISA plates (Thermo Fisher Scientific, Waltham, MA, USA.) were plated with the CV3-  
433 25 mAb at 0.05 µg per well overnight at 4°C. Unbound antibodies were removed by washing the  
434 plates twice with PBS. Plates were subsequently blocked with 3% BSA in PBS for 1 h at room  
435 temperature. After the washes, 200 µL of virus-containing supernatant was added to the wells.  
436 Viral capture by the Ab was visualized by adding 1×10<sup>4</sup> SARS-CoV-2-resistant Cf2Th cells in full  
437 DMEM medium per well. Forty-eight hours post-infection, cells were lysed by the addition of 30  
438 µL of passive lysis buffer (Promega, Madison, WI, USA.) and three freeze-thaw cycles. An LB941  
439 TriStar luminometer (Berthold Technologies) was used to measure the luciferase activity of each  
440 well after the addition of 100 µL of luciferin buffer (15 mM MgSO<sub>4</sub>, 15 mM KH<sub>2</sub>PO<sub>4</sub> (pH 7.8), 1  
441 mM ATP, and 1 mM dithiothreitol) and 50 µL of 1 mM D-luciferin potassium salt (Prolume,  
442 Randolph, VT, USA.).

443

444

445 **QUANTIFICATION AND STATISTICAL ANALYSIS**

446 **Statistical analysis**

447 Symbols represent biologically independent samples from SARS-CoV-2 naïve, BTI or PI  
448 individuals. Statistics were analyzed using GraphPad Prism version 8.0.1 (GraphPad, San Diego,  
449 CA). Every dataset was tested for statistical normality and this information was used to apply the  
450 appropriate (parametric or nonparametric) statistical test. p values < 0.05 were considered  
451 significant; significance values are indicated as \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001, ns,  
452 non-significant.

453

454 **SUPPLEMENTAL INFORMATION**

455 Supplemental information can be found online at ...

## 456 REFERENCES

- 457 1. Viana, R., Moyo, S., Amoako, D.G., Tegally, H., Scheepers, C., Althaus, C.L., Anyaneji, U.J.,  
458 Bester, P.A., Boni, M.F., Chand, M., et al. (2022). Rapid epidemic expansion of the SARS-  
459 CoV-2 Omicron variant in southern Africa. *Nature*, 1–10. 10.1038/s41586-022-04411-y.
- 460 2. WHO Update on Omicron, <https://www.who.int/news/item/28-11-2021-update-on-omicron>.  
461 <https://www.who.int/news/item/28-11-2021-update-on-omicron>.
- 462 3. CDC (2022). COVID Data Tracker Weekly Review, [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/past-reports/04222022.html)  
463 [ncov/covid-data/covidview/past-reports/04222022.html](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/past-reports/04222022.html). *Cent. Dis. Control Prev.*  
464 [https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/past-](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/past-reports/04222022.html)  
465 [reports/04222022.html](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/past-reports/04222022.html).
- 466 4. Elliott, P., Eales, O., Steyn, N., Tang, D., Bodinier, B., Wang, H., Elliott, J., Whitaker, M.,  
467 Atchison, C., Diggle, P.J., et al. (2022). Twin peaks: The Omicron SARS-CoV-2 BA.1 and  
468 BA.2 epidemics in England. *Science* 376, eabq4411. 10.1126/science.abq4411.
- 469 5. Mohapatra, R.K., Kandi, V., Sarangi, A.K., Verma, S., Tuli, H.S., Chakraborty, S.,  
470 Chakraborty, C., and Dhama, K. (2022). The recently emerged BA.4 and BA.5 lineages of  
471 Omicron and their global health concerns amid the ongoing wave of COVID-19 pandemic –  
472 Correspondence. *Int. J. Surg. Lond. Engl.* 103, 106698. 10.1016/j.ijisu.2022.106698.
- 473 6. PHO (2022). Public Health Ontario : SARS-CoV-2 Omicron Variant Sub-Lineages BA.4 and  
474 BA.5: Evidence and Risk Assessment, [chrome-](https://www.publichealthontario.ca/-/media/Documents/nCoV/voc/2022/07/evidence-brief-ba4-ba5-risk-assessment-jul-8.pdf?sc_lang=en)  
475 [extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.publichealthontario.ca/-](https://www.publichealthontario.ca/-/media/Documents/nCoV/voc/2022/07/evidence-brief-ba4-ba5-risk-assessment-jul-8.pdf?sc_lang=en)  
476 [/media/Documents/nCoV/voc/2022/07/evidence-brief-ba4-ba5-risk-assessment-jul-](https://www.publichealthontario.ca/-/media/Documents/nCoV/voc/2022/07/evidence-brief-ba4-ba5-risk-assessment-jul-8.pdf?sc_lang=en)  
477 [8.pdf?sc\\_lang=en](https://www.publichealthontario.ca/-/media/Documents/nCoV/voc/2022/07/evidence-brief-ba4-ba5-risk-assessment-jul-8.pdf?sc_lang=en).
- 478 7. Tegally, H., Moir, M., Everatt, J., Giovanetti, M., Scheepers, C., Wilkinson, E., Subramoney,  
479 K., Makatini, Z., Moyo, S., Amoako, D.G., et al. (2022). Emergence of SARS-CoV-2 Omicron  
480 lineages BA.4 and BA.5 in South Africa. *Nat. Med.*, 1–1. 10.1038/s41591-022-01911-2.
- 481 8. Yamasoba, D., Kosugi, Y., Kimura, I., Fujita, S., Uriu, K., Ito, J., and Sato, K. (2022).  
482 Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal  
483 antibodies. *Lancet Infect. Dis.* 22, 942–943. 10.1016/S1473-3099(22)00365-6.
- 484 9. WHO (2022). Tracking SARS-CoV-2 variants, [https://www.who.int/en/activities/tracking-](https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)  
485 [SARS-CoV-2-variants/](https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/). [https://www.who.int/health-topics/typhoid/tracking-SARS-CoV-2-](https://www.who.int/health-topics/typhoid/tracking-SARS-CoV-2-variants/)  
486 [variants/](https://www.who.int/health-topics/typhoid/tracking-SARS-CoV-2-variants/).
- 487 10. IDSA (2022). SARS-CoV-2 Variants, [https://www.idsociety.org/covid-19-real-time-learning-](https://www.idsociety.org/covid-19-real-time-learning-network/emerging-variants/emerging-covid-19-variants/)  
488 [network/emerging-variants/emerging-covid-19-variants/](https://www.idsociety.org/covid-19-real-time-learning-network/emerging-variants/emerging-covid-19-variants/). [https://www.idsociety.org/covid-19-](https://www.idsociety.org/covid-19-real-time-learning-network/emerging-variants/emerging-covid-19-variants/)  
489 [real-time-learning-network/emerging-variants/emerging-covid-19-variants/](https://www.idsociety.org/covid-19-real-time-learning-network/emerging-variants/emerging-covid-19-variants/).
- 490 11. Muik, A., Lui, B.G., Wallisch, A.-K., Bacher, M., Mühl, J., Reinholz, J., Ozhelvaci, O.,  
491 Beckmann, N., Güimil Garcia, R. de la C., Poran, A., et al. (2022). Neutralization of SARS-  
492 CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. *Science* 375, 678–680.  
493 10.1126/science.abn7591.

- 494 12. Nemet, I., Kliker, L., Lustig, Y., Zuckerman, N., Erster, O., Cohen, C., Kreiss, Y., Alroy-Preis,  
495 S., Regev-Yochay, G., Mendelson, E., et al. (2022). Third BNT162b2 Vaccination  
496 Neutralization of SARS-CoV-2 Omicron Infection. *N. Engl. J. Med.* 386, 492–494.  
497 10.1056/NEJMc2119358.
- 498 13. Yu, J., Collier, A.Y., Rowe, M., Mardas, F., Ventura, J.D., Wan, H., Miller, J., Powers, O.,  
499 Chung, B., Siamatu, M., et al. (2022). Neutralization of the SARS-CoV-2 Omicron BA.1 and  
500 BA.2 Variants. *N. Engl. J. Med.* 386, 1579–1580. 10.1056/NEJMc2201849.
- 501 14. Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S.Y., Boutin, M., Bourassa, C., Beaudoin-  
502 Bussièrès, G., Bo, Y., Ding, S., Laumaea, A., et al. (2022). SARS-CoV-2 Omicron Spike  
503 recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-  
504 week interval between doses. *Cell Rep.*, 110429. 10.1016/j.celrep.2022.110429.
- 505 15. Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N.,  
506 Faustini, S., Al-Taei, S., Moore, S.C., et al. (2021). Immunogenicity of standard and extended  
507 dosing intervals of BNT162b2 mRNA vaccine. *Cell* 184, 5699-5714.e11.  
508 10.1016/j.cell.2021.10.011.
- 509 16. Tauzin, A., Gong, S.Y., Chatterjee, D., Ding, S., Painter, M.M., Goel, R.R., Beaudoin-  
510 Bussièrès, G., Marchitto, L., Boutin, M., Laumaea, A., et al. (2022). A boost with SARS-CoV-  
511 2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval  
512 between the first two doses. *Cell Rep.* 41. 10.1016/j.celrep.2022.111554.
- 513 17. Kurhade, C., Zou, J., Xia, H., Cai, H., Yang, Q., Cutler, M., Cooper, D., Muik, A., Jansen, K.U.,  
514 Xie, X., et al. (2022). Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses  
515 of BNT162b2 vaccine. *Nat. Commun.* 13, 3602. 10.1038/s41467-022-30681-1.
- 516 18. Kitchin, D., Richardson, S.I., van der Mescht, M.A., Motlou, T., Mzindle, N., Moyo-Gwete, T.,  
517 Makhado, Z., Ayres, F., Manamela, N.P., Spencer, H., et al. (2022). Ad26.COV2.S  
518 breakthrough infections induce high titers of neutralizing antibodies against Omicron and  
519 other SARS-CoV-2 variants of concern. *Cell Rep. Med.* 3, 100535.  
520 10.1016/j.xcrm.2022.100535.
- 521 19. Miyamoto, S., Arashiro, T., Adachi, Y., Moriyama, S., Kinoshita, H., Kanno, T., Saito, S.,  
522 Katano, H., Iida, S., Aina, A., et al. (2022). Vaccination-infection interval determines cross-  
523 neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.  
524 *Med*, S2666634022000897. 10.1016/j.medj.2022.02.006.
- 525 20. Qu, P., Faraone, J., Evans, J.P., Zou, X., Zheng, Y.-M., Carlin, C., Bednash, J.S., Lozanski,  
526 G., Mallampalli, R.K., Saif, L.J., et al. (2022). Neutralization of the SARS-CoV-2 Omicron  
527 BA.4/5 and BA.2.12.1 Subvariants. *N. Engl. J. Med.* 386, 2526–2528.  
528 10.1056/NEJMc2206725.
- 529 21. Tuekprakhon, A., Nutalai, R., Djokaite-Guraliuc, A., Zhou, D., Ginn, H.M., Selvaraj, M., Liu,  
530 C., Mentzer, A.J., Supasa, P., Duyvesteyn, H.M.E., et al. (2022). Antibody escape of SARS-  
531 CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. *Cell* 185, 2422-2433.e13.  
532 10.1016/j.cell.2022.06.005.

- 533 22. Wang, Q., Guo, Y., Iketani, S., Nair, M.S., Li, Z., Mohri, H., Wang, M., Yu, J., Bowen, A.D.,  
534 Chang, J.Y., et al. (2022). Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1,  
535 BA.4, & BA.5. *Nature*, 1–3. 10.1038/s41586-022-05053-w.
- 536 23. Shen, X., Chalkias, S., Feng, J., Chen, X., Zhou, H., Marshall, J.-C., Girard, B., Tomassini,  
537 J.E., Aunins, A., Das, R., et al. (2022). Neutralization of SARS-CoV-2 Omicron BA.2.75 after  
538 mRNA-1273 Vaccination. *N. Engl. J. Med.* 387, 1234–1236. 10.1056/NEJMc2210648.
- 539 24. Sheward, D.J., Kim, C., Fischbach, J., Sato, K., Muschiol, S., Ehling, R.A., Björkström, N.K.,  
540 Hedestam, G.B.K., Reddy, S.T., Albert, J., et al. (2022). Omicron sublineage BA.2.75.2  
541 exhibits extensive escape from neutralising antibodies. *Lancet Infect. Dis.* 0. 10.1016/S1473-  
542 3099(22)00663-6.
- 543 25. Arora, P., Kempf, A., Nehlmeier, I., Schulz, S.R., Jäck, H.-M., Pöhlmann, S., and Hoffmann,  
544 M. (2022). Omicron sublineage BQ.1.1 resistance to monoclonal antibodies. *Lancet Infect.*  
545 *Dis.* 0. 10.1016/S1473-3099(22)00733-2.
- 546 26. Kurhade, C., Zou, J., Xia, H., Liu, M., Chang, H.C., Ren, P., Xie, X., and Shi, P.-Y. (2022).  
547 Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of  
548 parental mRNA vaccine or a BA.5-bivalent booster. 2022.10.31.514580.  
549 10.1101/2022.10.31.514580.
- 550 27. Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S.Y., Gasser, R., Beaudoin-Bussièrès, G.,  
551 Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021). A single dose of the SARS-  
552 CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell  
553 responses. *Cell Host Microbe* 0. 10.1016/j.chom.2021.06.001.
- 554 28. Tauzin, A., Gong, S.Y., Beaudoin-Bussièrès, G., Vézina, D., Gasser, R., Nault, L., Marchitto,  
555 L., Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2022). Strong humoral immune responses  
556 against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval  
557 between doses. *Cell Host Microbe* 30, 97-109.e5. 10.1016/j.chom.2021.12.004.
- 558 29. Prévost, J., Gasser, R., Beaudoin-Bussièrès, G., Richard, J., Duerr, R., Laumaea, A., Anand,  
559 S.P., Goyette, G., Benlarbi, M., Ding, S., et al. (2020). Cross-Sectional Evaluation of Humoral  
560 Responses against SARS-CoV-2 Spike. *Cell Rep. Med.* 1, 100126.  
561 10.1016/j.xcrm.2020.100126.
- 562 30. Anand, S.P., Prévost, J., Nayrac, M., Beaudoin-Bussièrès, G., Benlarbi, M., Gasser, R.,  
563 Brassard, N., Laumaea, A., Gong, S.Y., Bourassa, C., et al. (2021). Longitudinal analysis of  
564 humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months  
565 post-symptom onset. *Cell Rep. Med.*, 100290. 10.1016/j.xcrm.2021.100290.
- 566 31. Tauzin, A., Gendron-Lepage, G., Nayrac, M., Anand, S.P., Bourassa, C., Medjahed, H.,  
567 Goyette, G., Dubé, M., Bazin, R., Kaufmann, D.E., et al. (2022). Evolution of Anti-RBD IgG  
568 Avidity Following SARS-CoV-2 Infection. *Viruses* 14, 532. 10.3390/v14030532.
- 569 32. Nayrac, M., Dubé, M., Sannier, G., Nicolas, A., Marchitto, L., Tastet, O., Tauzin, A., Brassard,  
570 N., Lima-Barbosa, R., Beaudoin-Bussièrès, G., et al. (2022). Temporal associations of B and  
571 T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen.  
572 *Cell Rep.* 0. 10.1016/j.celrep.2022.111013.



- 573 33. Li, W., Chen, Y., Prévost, J., Ullah, I., Lu, M., Gong, S.Y., Tauzin, A., Gasser, R., Vézina, D.,  
574 Anand, S.P., et al. (2022). Structural basis and mode of action for two broadly neutralizing  
575 antibodies against SARS-CoV-2 emerging variants of concern. *Cell Rep.* 38, 110210.  
576 10.1016/j.celrep.2021.110210.
- 577 34. Prévost, J., Richard, J., Gasser, R., Ding, S., Fage, C., Anand, S.P., Adam, D., Vergara, N.G.,  
578 Tauzin, A., Benlarbi, M., et al. (2021). Impact of temperature on the affinity of SARS-CoV-2  
579 Spike glycoprotein for host ACE2. *J. Biol. Chem.*, 101151. 10.1016/j.jbc.2021.101151.
- 580 35. Ullah, I., Prévost, J., Ladinsky, M.S., Stone, H., Lu, M., Anand, S.P., Beaudoin-Bussi eres, G.,  
581 Symmes, K., Benlarbi, M., Ding, S., et al. (2021). Live imaging of SARS-CoV-2 infection in  
582 mice reveals that neutralizing antibodies require Fc function for optimal efficacy. *Immunity*,  
583 S1074-7613(21)00347-2. 10.1016/j.immuni.2021.08.015.
- 584 36. Gruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F.,  
585 Sander, L.E., and Klein, F. (2022). mRNA booster immunization elicits potent neutralizing  
586 serum activity against the SARS-CoV-2 Omicron variant. *Nat. Med.*, 1–4. 10.1038/s41591-  
587 021-01676-0.
- 588 37. Garrett, N., Tapley, A., Andriesen, J., Seocharan, I., Fisher, L.H., Bunts, L., Espy, N., Wallis,  
589 C.L., Randhawa, A.K., Ketter, N., et al. (2022). High Rate of Asymptomatic Carriage  
590 Associated with Variant Strain Omicron. *medRxiv*, 2021.12.20.21268130.  
591 10.1101/2021.12.20.21268130.
- 592 38. Sun, K., Tempia, S., Kleynhans, J., von Gottberg, A., McMorrow, M.L., Wolter, N., Bhiman,  
593 J.N., Moyes, J., du Plessis, M., Carrim, M., et al. (2022). SARS-CoV-2 transmission,  
594 persistence of immunity, and estimates of Omicron’s impact in South African population  
595 cohorts. *Sci. Transl. Med.* 0, eabo7081. 10.1126/scitranslmed.abo7081.
- 596 39. Altarawneh, H.N., Chemaitelly, H., Ayoub, H.H., Hasan, M.R., Coyle, P., Yassine, H.M., Al-  
597 Khatib, H.A., Benslimane, F.M., Al-Kanaani, Z., Al-Kuwari, E., et al. (2022). Protection of  
598 SARS-CoV-2 natural infection against reinfection with the Omicron BA.4 or BA.5 subvariants.  
599 2022.07.11.22277448. 10.1101/2022.07.11.22277448.
- 600 40. Carazo, S., Skowronski, D.M., Brisson, M., Sauvageau, C., Brousseau, N., Gilca, R., Ouakki,  
601 M., Barkati, S., Fafard, J., Talbot, D., et al. (2022). Protection against Omicron re-infection  
602 conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination.  
603 2022.04.29.22274455. 10.1101/2022.04.29.22274455.
- 604 41. Goel, R.R., Apostolidis, S.A., Painter, M.M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma,  
605 S., Hicks, P., Meng, W., Rosenfeld, A.M., et al. (2021). Distinct antibody and memory B cell  
606 responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. *Sci.*  
607 *Immunol.* 6. 10.1126/sciimmunol.abi6950.
- 608 42. Valcourt, E.J., Manguiat, K., Robinson, A., Lin, Y.-C., Abe, K.T., Mubareka, S., Shigayeva,  
609 A., Zhong, Z., Girardin, R.C., DuPuis, A., et al. (2021). Evaluating Humoral Immunity against  
610 SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory  
611 Comparison of Conventional and Surrogate Neutralization Assays. *Microbiol. Spectr.* 9,  
612 e0088621. 10.1128/Spectrum.00886-21.

- 613 43. Sun, H., Xu, J., Zhang, G., Han, J., Hao, M., Chen, Z., Fang, T., Chi, X., and Yu, C. (2022).  
614 Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-  
615 2 Variants. *Viruses* 14, 1332. 10.3390/v14061332.
- 616 44. Wang, Z., Muecksch, F., Muenn, F., Cho, A., Zong, S., Raspe, R., Ramos, V., Johnson, B.,  
617 Ben Tanfous, T., DaSilva, J., et al. (2022). Humoral immunity to SARS-CoV-2 elicited by  
618 combination COVID-19 vaccination regimens. *J. Exp. Med.* 219, e20220826.  
619 10.1084/jem.20220826.
- 620 45. Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z.,  
621 Gaebler, C., Caskey, M., Nussenzweig, M.C., et al. (2022). Plasma Neutralization of the  
622 SARS-CoV-2 Omicron Variant. *N. Engl. J. Med.* 386, 599–601. 10.1056/NEJMc2119641.
- 623 46. Robbiani, D.F., Gaebler, C., Muecksch, F., Lorenzi, J.C.C., Wang, Z., Cho, A., Agudelo, M.,  
624 Barnes, C.O., Gazumyan, A., Finkin, S., et al. (2020). Convergent antibody responses to  
625 SARS-CoV-2 in convalescent individuals. *Nature* 584, 437–442. 10.1038/s41586-020-2456-  
626 9.
- 627 47. Jennewein, M.F., MacCamy, A.J., Akins, N.R., Feng, J., Homad, L.J., Hurlburt, N.K.,  
628 Seydoux, E., Wan, Y.-H., Stuart, A.B., Edara, V.V., et al. (2021). Isolation and characterization  
629 of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. *Cell Rep.* 36, 109353.  
630 10.1016/j.celrep.2021.109353.
- 631 48. Gong, S.Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., Gasser, R., Bo, Y., Vézina,  
632 D., Goyette, G., Gendron-Lepage, G., et al. (2021). Contribution of single mutations to  
633 selected SARS-CoV-2 emerging variants spike antigenicity. *Virology* 563, 134–145.  
634 10.1016/j.virol.2021.09.001.
- 635 49. Tauzin, A., Gong, S.Y., Beaudoin-Bussièrès, G., Vézina, D., Gasser, R., Nault, L., Marchitto,  
636 L., Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2022). Strong humoral immune responses  
637 against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval  
638 between doses. *Cell Host Microbe* 30, 97-109.e5. 10.1016/j.chom.2021.12.004.
- 639 50. Beaudoin-Bussièrès, G., Laumaea, A., Anand, S.P., Prévost, J., Gasser, R., Goyette, G.,  
640 Medjahed, H., Perreault, J., Tremblay, T., Lewin, A., et al. (2020). Decline of Humoral  
641 Responses against SARS-CoV-2 Spike in Convalescent Individuals. *mBio* 11.  
642 10.1128/mBio.02590-20.
- 643 51. Ding, S., Laumaea, A., Benlarbi, M., Beaudoin-Bussièrès, G., Gasser, R., Medjahed, H.,  
644 Pancera, M., Stamatatos, L., McGuire, A.T., Bazin, R., et al. (2020). Antibody Binding to  
645 SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization. *Viruses* 12,  
646 1214. 10.3390/v12111214.

647











Figure 2



**Table S1. Flow cytometry antibody staining panel for B cells characterization. Related to Figure 1 and the STAR Methods section.**

<b>Marker-Fluorophore</b>	<b>Clone</b>	<b>Vendor</b>	<b>Catalog #</b>
CD3 – BV480	UCHT1	BD Biosciences	566105
CD14 – BV480	M5E2	BD Biosciences	746304
CD16 – BV480	3G8	BD Biosciences	566108
CD19 – BV650	SJ25C1	Biolegend	363026
CD20 – BV711	2H7	Biolegend	302342
CD21 – BV786	B-LY4	BD Biosciences	740969
CD24 – BUV805	ML5	BD Biosciences	742010
CD27 – APC-R700	M-T271	BD Biosciences	565116
CD38 – BB790	HIT2	BD Biosciences	CUSTOM
CD56 – BV480	NCAM16.2	BD Biosciences	566124
CD138 – BUV661	MI15	BD Biosciences	749873
CCR10 – BUV395	1B5	BD Biosciences	565322
HLA-DR – BB700	G46-6	BD Biosciences	566480
IgA - PE	IS11-8E10	Miltenyi Biotec	130-113-476
IgD – BUV563	IA6-2	BD Biosciences	741394
IgG – BV421	G18-147	BD Biosciences	562581
IgM – BUV737	UCH-B1	BD Biosciences	748928
LIVE/DEAD Fixable dead cell	N/A	Thermo Fisher Scientific	L34960



**A****B****Full-Spike binding****C****Virus capture assay****D****Infectivity****Figure S2. Recognition and infectivity of different Omicron subvariant Spikes, Related to Figures 2 and 3.**

(A) Mutations and deletions in the Spike amino acid sequence from D614G and Omicron subvariants compared to the ancestral strain. NTD: N-terminal domain; RBD: receptor-binding domain; RBM : receptor-binding motif; SD2: subdomain 2; S2: subunit 2. (B) 293T cells were transfected with the full-length Spike from different SARS-CoV-2 variants (D614G, BA.2, BA.4/5, BA.2.75, BA.4.6 and BQ.1.1), stained with the CV3-25 mAb and analyzed by flow cytometry. (C) VSV-G-pseudotyped viral particles expressing the indicated SARS-CoV-2 S glycoprotein were added to plates coated with CV3-25. Free virions were washed away, and Cf2Th cells were added to the wells. After 48 hours, cells were lysed, and the luciferase activity was measured. Luciferase signals were normalized to those obtained with the CV3-25 mAb. (D) Pseudoviral particles bearing the indicated SARS-CoV-2 S were used to infect 293T-ACE2 cells for 2 days at 37°C. RLU values obtained were normalized to D614G. (C-D) The experiments were repeated three times. Error bars indicate means  $\pm$  SEM.